Share on LinkedInShare on LinkedIn

ARTICLE · 07 SEPTEMBER 2016

Eli Lilly's Erectile Dysfunction Patent Stands Up To Scrutiny

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

The English High Court (Patents Court) has ruled in a patent dispute concerned with the treatment of erectile dysfunction.

United KingdomIntellectual Property

The English High Court (Patents Court) has ruled in a patent dispute concerned with the treatment of erectile dysfunction. Actavis and Mylan had commenced "clear the way" litigation by seeking to revoke Eli Lilly's patent in order to launch generic versions of its CIALIS medicine upon expiry of the relevant SPC protection (November 2017).

One of Eli Lilly's patents, regarding the dosage of CIALIS (EP(UK) 1,173,181), was found to be valid and infringed. The other patent, regarding microparticulate formulation of the active ingredient (tadalafil) (EP(UK) 1,200,092), was invalid.

The case involved multiple claimants, including Actavis and Mylan, across several joined cases. The judgment is long and complex, but there are some take-home messages for patentees and potential litigants that should not be missed.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from